Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS +1.46%90 EV-to-EBITDA is 7.48 as of Aug. 22, 2026, which is 11% above its 10-year median of 6.72. GuruFocus rates ASX:VLS with a GF Score™ of 90/100 and a GF Value™ of A$2.63 (Fairly Valued). The stock has 6 warning signs investors should review. Among 739 Drug Manufacturers companies, Vita Life Sciences ranks better than 73.34% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vita Life Sciences's enterprise value is A$119.50 Mil.
Vita Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was A$15.98 Mil. Therefore, Vita Life Sciences's EV-to-EBITDA for today is 7.48.
The historical rank and industry rank for Vita Life Sciences's EV-to-EBITDA or its related term are showing as below:
ASX:VLS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.91 Med: 6.72 Max: 12.64
Current: 7.48
During the past 13 years, the highest EV-to-EBITDA of Vita Life Sciences was 12.64. The lowest was 3.91. And the median was 6.72.
ASX:VLS's EV-to-EBITDA is ranked better than 73.34% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs ASX:VLS: 7.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vita Life Sciences (ASX:VLS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vita Life Sciences's PE Ratio (TTM) for today is calculated as:
Vita Life Sciences's share price for today is A$2.78.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.197.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vita Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's EV-to-EBITDA falls into.
Vita Life Sciences's current Enterprise Value is A$119.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was A$15.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a EV-to-EBITDA of 7.48 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vita Life Sciences. This is 11% above median its historical median of 6.72. Over the past decade, Vita Life Sciences' EV-to-EBITDA has ranged from 3.91 to 12.64. According to the industry distribution chart, Vita Life Sciences ranks #197 out of 739 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Vita Life Sciences' EV-to-EBITDA too high?
Vita Life Sciences' current EV-to-EBITDA of 7.48 is 11% above median its 10-year median of 6.72. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 12.64. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. Vita Life Sciences' value of 7.48 is 42.3% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #197 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #197 out of 739 companies for EV-to-EBITDA. This puts Vita Life Sciences in the upper half of its industry. The industry median EV-to-EBITDA is 12.97. Vita Life Sciences' value of 7.48 is 42.3% below this benchmark. Historically, Vita Life Sciences' own EV-to-EBITDA has ranged from 3.91 to 12.64 over the past decade. While the company's 10-year median is 6.72 vs. the industry median of 12.97, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current EV-to-EBITDA of 7.48 is 42.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vita Life Sciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current EV-to-EBITDA is 7.48, which is 11% above median its own 10-year median of 6.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.63, compared to a current price of A$2.78 — trading 5.7% above its estimated fair value. The current EV-to-EBITDA is 7.48, which is 11% above median its 10-year median of 6.72 and 42.3% below the Drug Manufacturers industry median of 12.97. Vita Life Sciences' overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current EV-to-EBITDA is 7.48 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.78 is trading 5.7% above its estimated GF Value™ of A$2.63.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
EV-to-EBITDA: 7.48 (11% above median its 10-year median of 6.72)
GF Value™: A$2.63 vs. price of A$2.78 (5.7% above fair value)
Industry Position: 42.3% below the Drug Manufacturers median (#197 of 739)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
90GF Score
Get the complete analysis for ASX:VLS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
